Abstract: In certain embodiments, a method for detecting a prostate proliferative cell disorder, a prostate cancer or a prostate tumor and/or categorizing Gleason's Sum of the tumors includes performing a digital rectal examination on a subject; obtaining one or more expressed prostatic secretion (EPS) samples from the subject; measuring PSA levels in the EPS; and measuring a biomarker, wherein the biomarker is TMPRSS2:ERG fusion RNA. Optionally, the biomarker may be methylated copies of GSTPI, APC, RARB and/or RASSFI DNA or PCA3 RNA. A kit for performing any of the above embodiments is also contemplated.